武田制药富马酸伏诺拉生片根除幽门螺杆菌新适应症在中国获批
善平
发表于 2023-11-24 16:32:16
1226
0
0
据悉,以富马酸伏诺拉生片为基础的四联方案是国内目前首个获批的、用以根除幽门螺杆菌含铋四联方案。研究数据显示,基于富马酸伏诺拉生的幽门螺杆菌根除新方案根除率高达94.1%,该方案为中国人群中幽门螺杆菌根除率排名第一的方案。
公开资料显示,幽门螺杆菌是一种与多种重大慢性疾病相关的致病菌,具有传染性,可引发包括慢性胃炎、消化性溃疡、胃黏膜相关淋巴样组织淋巴瘤等多种胃肠道内外疾病。我国居民幽门螺杆菌感染率约为46.7%,家庭幽门螺杆菌感染率更是高达71.2%。
武田制药表示,消化作为武田制药布局中国市场的四大核心治疗领域之一,当前已经进入了全新的发展阶段;未来,企业将持续心系中国公众健康需求,深耕消化领域。据悉,富马酸伏诺拉生片与抗生素联用根除幽门螺杆菌的新适应症已在日本、美国等全球15个国家及地区获批。
CandyLake.com is an information publishing platform and only provides information storage space services.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.